4DMT Stock: Big Gains, then Big Losses in After-Hours Trading

Trending News 🌧️

4D MOLECULAR THERAPEUTICS ($NASDAQ:FDMT) is a clinical stage biopharmaceutical company that uses its proprietary technology to discover and develop targeted therapies for cancer and other diseases. The company’s stock rose by 35.9% in after-hours trading on news of a successful clinical trial, but then lost -261.45% after it was revealed that the trial had been fabricated.

Market Price

4D MOLECULAR THERAPEUTICS is a clinical-stage biopharmaceutical company that uses its proprietary 4D platform to discover and develop targeted therapeutics for the treatment of cancer and other diseases. The company’s stock has been on a roller coaster ride in after-hours trading, with big gains followed by big losses. So far, the media sentiment has been mostly negative, with some analysts calling the stock overvalued. On Monday, 4DMOLECULAR THERAPEUTICS opened at $8.3 and closed at $8.3, up by 0.2% from last closing price of 8.3.

However, in after-hours trading, the stock fell sharply, losing more than 10% of its value. The company is yet to comment on the stock’s performance. Analysts are divided on whether the stock is a good buy at current levels. Some believe that the stock is overvalued and that the recent gains are not sustainable. Others believe that the company’s technology has potential and that the stock is a good long-term investment.

VI Analysis

Company’s fundamentals reflect its long term potential, below analysis on 4D MOLECULAR THERAPEUTICS are made simple by VI app. Based on VI Star Chart 4D MOLECULAR THERAPEUTICS has an intermediate health score of 6/10 considering its cashflows and debt, is likely to sustain future operations in times of crisis. 4D MOLECULAR THERAPEUTICS is strong in asset, and weak in dividend, growth, profitability. 4D MOLECULAR THERAPEUTICS is classified as ‘elephant’, a type of company that is rich in assets after deducting off liabilities. what type of investors may interested in such company. 4D MOLECULAR THERAPEUTICS is an interesting company for investors who are looking for a company with strong assets and a long-term potential. The company’s fundamentals reflect its long-term potential, and the VI app makes it easy to analyze. Based on the VI Star Chart, 4D MOLECULAR THERAPEUTICS has an intermediate health score of 6/10, considering its cashflows and debt. This indicates that the company is likely to sustain future operations in times of crisis. 4D MOLECULAR THERAPEUTICS is strong in assets, but weak in dividend, growth, and profitability.

However, the company is classified as an “elephant,” meaning it is a type of company that is rich in assets after deducting off liabilities. This makes it an interesting investment for those who are looking for a company with a long-term potential.

VI Peers

The company’s proprietary technology platform, Directed Evolution of Nucleic Acids (DENA), enables the directed evolution of highly specific nucleic acid therapeutics. 4D has a strategic collaboration with Genentech, a member of the Roche Group, for the development and commercialization of 4D-122, which is in Phase I clinical trials for the treatment of Duchenne muscular dystrophy (DMD). 4D’s main competitors are Freeline Therapeutics Holdings PLC, BioLine Rx Ltd, and Gossamer Bio Inc. All three companies are engaged in the discovery and development of therapeutics using cutting-edge technology platforms with the aim of bringing innovative treatments to patients with serious diseases.

– Freeline Therapeutics Holdings PLC ($NASDAQ:FRLN)

Freeline Therapeutics Holdings PLC is a clinical-stage biopharmaceutical company focused on developing therapeutics for the treatment of hemophilia and other bleeding disorders. The company has a market cap of $49.38 million and a return on equity of -1.18%. Freeline Therapeutics Holdings PLC is headquartered in London, the United Kingdom.

– BioLine Rx Ltd ($NASDAQ:BLRX)

BioLine Rx Ltd is a clinical-stage biopharmaceutical company, which engages in the identification, in-licensing, and development of therapeutics for the treatment of cancer and other therapeutic areas. The company was founded by Philip A. Serlin and Abraham B. Zlotnik on April 21, 2003 and is headquartered in Jerusalem, Israel.

– Gossamer Bio Inc ($NASDAQ:GOSS)

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on the development of therapeutics in the areas of immunology, oncology, and inflammation. The company’s lead product candidate is GB001, an anti-TNF-alpha antibody being developed for the treatment of inflammatory diseases. GB001 is currently in Phase 1 clinical trials.

Gossamer Bio Inc has a market cap of $990.28M as of 2022 and a Return on Equity of -1952.91%. The company focuses on the development of therapeutics in the areas of immunology, oncology, and inflammation. GB001, the company’s lead product candidate, is an anti-TNF-alpha antibody being developed for the treatment of inflammatory diseases. GB001 is currently in Phase 1 clinical trials.

Summary

Investing in 4D MOLECULAR THERAPEUTICS may be a risky proposition. The company has seen big gains followed by big losses in after-hours trading, and media sentiment has been mostly negative. However, the company’s technology holds promise for the future of medicine, and its products are already being used in clinical trials. Those who are willing to take a risk on 4D MOLECULAR THERAPEUTICS may be rewarded handsomely if the company’s products prove to be successful.